Last reviewed · How we verify
Detralex — Competitive Intelligence Brief
marketed
Venoactive drug
Venous tone and microcirculation
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Detralex (Detralex) — Servier Russia. Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Detralex TARGET | Detralex | Servier Russia | marketed | Venoactive drug | Venous tone and microcirculation |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Venoactive drug class)
- Servier Russia · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Detralex CI watch — RSS
- Detralex CI watch — Atom
- Detralex CI watch — JSON
- Detralex alone — RSS
- Whole Venoactive drug class — RSS
Cite this brief
Drug Landscape (2026). Detralex — Competitive Intelligence Brief. https://druglandscape.com/ci/detralex. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab